Showing 1 – 20 of 28
Relevance | Newest | Oldest |
  • Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials

    Abstract Full Text
    free access is active quiz
    JAMA. 2020; 324(4):369-380. doi: 10.1001/jama.2020.9482

    This study reports 20-year breast cancer incidence among participants in Women’s Health Initiative (WHI) trials randomized to conjugated equine estrogen (CEE) alone or with medroxyprogesterone acetate vs placebo.

  • Comparison of Mortality Among Participants of Women’s Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers

    Abstract Full Text
    open access
    JAMA Netw Open. 2020; 3(6):e207227. doi: 10.1001/jamanetworkopen.2020.7227

    This cohort study uses data from the Women’s Health Initiative study to compare the prognostic features and mortality rate of women with interval breast cancers diagnosed within 1 year or between 1 and 2.5 years of a mammogram with negative results with the prognostic features and mortality rate of women with breast cancers detected by screening.

  • Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women

    Abstract Full Text
    open access has multimedia
    JAMA Netw Open. 2019; 2(7):e197337. doi: 10.1001/jamanetworkopen.2019.7337

    This cohort study uses data from women enrolled in the Women’s Health Initiative (WHI) to examine the associations of normal-weight central obesity with all-cause and cause-specific mortality among postmenopausal women in the United States.

  • Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study

    Abstract Full Text
    free access has multimedia
    JAMA Oncol. 2019; 5(2):155-163. doi: 10.1001/jamaoncol.2018.5327

    This secondary analysis of the Women’s Health Initiative randomized clinical trial and observational study cohort investigates the association between body fat and breast cancer risk in postmenopausal women with normal body mass index.

  • Notice of Retraction and Replacement. Tseng et al. Association of cataract surgery with mortality in older women: findings from the Women’s Health Initiative. JAMA Ophthalmol. 2018;136(1):3-10

    Abstract Full Text
    free access
    JAMA Ophthalmol. 2018; 136(11):1313-1314. doi: 10.1001/jamaophthalmol.2018.3347

    Notice of Retraction and Replacement. Tseng et al. Association of cataract surgery with mortality in older women: findings from the Women’s Health Initiative. JAMA Ophthalmol. 2018;136(1):3-10

  • Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trial

    Abstract Full Text
    free access online only
    JAMA Oncol. 2018; 4(10):e181212. doi: 10.1001/jamaoncol.2018.1212

    This secondary analysis of the Women’s Health Initiative randomized clinical trial investigates the association of a low-fat dietary pattern vs a usual diet comparison with overall survival among women with breast cancer.

  • Association of Cataract Surgery With Mortality in Older Women: Findings from the Women’s Health Initiative

    Abstract Full Text
    free access
    JAMA Ophthalmol. 2018; 136(1):3-10. doi: 10.1001/jamaophthalmol.2017.4512

    This cohort study examines the association between cataract surgery and total and cause-specific mortality in older patients with cataract in the Women’s Health Initiative.

  • Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials

    Abstract Full Text
    free access has multimedia
    JAMA. 2017; 318(10):927-938. doi: 10.1001/jama.2017.11217

    This observational follow-up (cumulative 18 years) of postmenopausal women enrolled in 2 RCTs compared rates of all-cause, cardiovascular, and cancer mortality between groups receiving hormone therapy (conjugated equine estrogens [CEE] plus medroxyprogesterone acetate) or CEE alone vs placebo.

  • Cardiovascular Disease After Aromatase Inhibitor Use

    Abstract Full Text
    free access
    JAMA Oncol. 2016; 2(12):1590-1597. doi: 10.1001/jamaoncol.2016.0429

    This cohort study compares the risk of cardiovascular disease in breast cancer survivors who received tamoxifen, aromatase inhibitors, both, or neither during a long-term follow-up period.

  • Association Between Obesity and Postmenopausal Breast Cancer Risk—Reply

    Abstract Full Text
    JAMA Oncol. 2015; 1(8):1171-1171. doi: 10.1001/jamaoncol.2015.3313
  • Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials

    Abstract Full Text
    free access
    JAMA Oncol. 2015; 1(3):296-305. doi: 10.1001/jamaoncol.2015.0494

    This study examined the influences of hormone therapy on breast cancer incidence during early and late postintervention phases in the Women’s Health Initiative trials, finding greater adverse influence for estrogen + progestin use and somewhat greater benefit for use of estrogen alone.

  • Hormone Therapy Use and Outcomes in the Women’s Health Initiative Trials—Reply

    Abstract Full Text
    JAMA. 2014; 311(4):417-418. doi: 10.1001/jama.2013.285163
  • Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials

    Abstract Full Text
    free access has multimedia
    JAMA. 2013; 310(13):1353-1368. doi: 10.1001/jama.2013.278040

    Manson and coauthors provide an update and overview of health outcomes during the intervention and poststopping phases of the Women’s Health Initiative (WHI) hormone therapy trials. In an accompanying Editorial, Nabel discusses how the WHI is a victory for women and their health.

  • Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy: A Randomized Controlled Trial

    Abstract Full Text
    free access
    JAMA. 2011; 305(13):1305-1314. doi: 10.1001/jama.2011.382
  • Breast Cancer in Postmenopausal Women After Hormone Therapy—Reply

    Abstract Full Text
    JAMA. 2011; 305(5):466-467. doi: 10.1001/jama.2011.76
  • Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women

    Abstract Full Text
    free access
    JAMA. 2010; 304(15):1684-1692. doi: 10.1001/jama.2010.1500
  • New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk

    Abstract Full Text
    free access
    Arch Intern Med. 2009; 169(18):1684-1691. doi: 10.1001/archinternmed.2009.303
  • Colorectal Cancer in Women After Stopping Postmenopausal Hormone Therapy—Reply

    Abstract Full Text
    JAMA. 2008; 299(23):2744-2745. doi: 10.1001/jama.299.23.2744-b
  • Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin

    Abstract Full Text
    free access
    JAMA. 2008; 299(9):1036-1045. doi: 10.1001/jama.299.9.1036
  • Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy

    Abstract Full Text
    free access
    Arch Intern Med. 2008; 168(4):370-377. doi: 10.1001/archinternmed.2007.123